Jubilant Pharmova posts ₹8,280 cr revenue, adds oncology client to Montreal facility
FY26 revenue grew 14% while EBITDA rose 8%. The CDMO unit added a global oncology product and is remediating its Montreal plant.
— 9 earlier stories on Jubilant Pharmova Ltd. →What's new
- FY26 revenue rose 14% to ₹8,280 crore; EBITDA grew 8% to ₹1,326 crore.
- CDMO unit onboarded a 'world-leading oncology product' on Montreal Line 3.
- Montreal facility remediation is progressing.
Why this matters
The numbers are solid but were fully anticipated. The real news is the oncology client win, which signals the Montreal plant is regaining commercial credibility after its well-publicized FDA warning-letter issues. That remediation progress is the operational story to track.
What we're watching
- Timeline for Montreal FDA clearance and full commercial ramp of the new oncology line.
- Whether the CDMO client win translates into meaningful FY27 revenue.
- Margin trajectory as the remediation costs fall away.
The full read
Jubilant Pharmova closed FY26 with 14% revenue growth to ₹8,280 crore. EBITDA rose 8% to ₹1,326 crore, implying a margin of roughly 16%. These numbers were expected. The operational development that matters is the CDMO unit landing a 'world-leading oncology product' on Montreal's Line 3. That client win, combined with the note that Montreal remediation is progressing, is the clearest signal yet that the plant is moving past its FDA warning-letter crisis. For investors, the financials are table stakes. The real test is whether the new oncology contract scales into material FY27 revenue and whether the remediation costs unwind to lift margins.
Questions answered
- What drove the 14% revenue growth in FY26?
- The filing provides segment-wise financials but does not break down the growth drivers in the summary. The key operational highlight is the CDMO segment winning a new oncology client for its Montreal facility.
- What is the status of the Montreal remediation?
- The company states that remediation at the Montreal facility is progressing. The onboarding of a new oncology product on Line 3 suggests the plant is nearing operational readiness.
- Why is the oncology client win significant?
- It marks a major commercial validation for the Montreal facility, which has been under regulatory scrutiny. Landing a 'world-leading' product indicates the plant's quality systems are being accepted by global pharma clients.
- How does the EBITDA margin look?
- EBITDA of ₹1,326 crore on revenue of ₹8,280 crore implies a margin of roughly 16%. This is down from the prior year's implied margin, suggesting some cost pressure or mix effects during the year.
Jubilant Pharmova Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on JUBLPHARMA →- 22 May 2026 · 2:54 PM IST Jubilant Pharmova posts ₹8,280 cr revenue, adds oncology client to Montreal facility
- 6d ago Jubilant Pharmova's ₹53.37 cr tax setback
- 12d ago Jubilant Pharmova's ₹107.89 cr tax demand cut to ₹42.41 cr
- 17d ago Jubilant Pharmova's Spokane plant gets 8 FDA observations, none on sterility
- 38d ago USFDA hits Jubilant's Montreal plant with a Warning Letter